Cyclosporine: Immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug
Transplant Immunology · 2025
DOI: 10.1016/j.trim.2024.102147 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant Immunology, 2025. Verfasst von Razan Alqadi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, King Saud Hospital, Unaizah, Qassim 56249, Saudi Arabia. Hauptthemen laut MEDLINE: Cyclosporine, Immunosuppressive Agents, Graft Rejection, Organ Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 149 Literaturangaben.
Abstract (Originalsprache)
The discovery and use of cyclosporine since its inception into the clinics in the '70s and up have played a crucial role in advancing transplant therapy, and containment of the immune-based rejections. The drug has improved the high rates of acute rejections and has supported early graft survival. However, the long-term survival of renal allografts is still less prevalent, and an in-depth analysis, as well as reported findings led us to believe that there is a chronic irreversible component to the drug, that is tackled through its metabolites, and that causes toxicity, which has led to new therapies, including monoclonal antibody-based medications. A recap of the immunosuppressive effects, and entwined toxicity of the drug, now relegated primarily to bone marrow early transplants, is being overviewed for the past protocols that were used to minimize, and avoid, or use this calcineurin inhibitor class of drug, cyclosporine, in combination with other drugs. The current review circumvents the cyclosporine's mechanism of action, pathophysiology, cytochrome roles, and other factors associated with acute and chronic toxicity developments. The review also attempts to find conclusive strategies reported in the recent studies to avoid its toxic side effects, and develop a safe-use strategy for the drug. Gastrointestinal decontamination, supporting the airway, monitoring for signs of respiratory insufficiency, monitoring for severe reactions, such as seizures, need for administration of oxygen, and avoiding the administration of drugs, that increase the blood levels of the cyclosporine, are beneficial interventions, when encountering cyclosporine toxicity cases. The constrained therapeutic outcomes have also led to redesign, and making use of combined formulations to reassess the pharmacokinetics of the drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, King Saud Hospital, Unaizah, Qassim 56249, Saudi Arabia.
- Department of Pharmacy, King Fahd Specialist Hospital, Buraydah, Qassim 52719, Saudi Arabia.
- Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.
- Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia. Electronic address: ri.khan@qu.edu.sa.
Zitieren
APA
Alqadi, R., Alqumia, A., Alhomoud, I. S., Alhowail, A., Aldubayan, M., Mohammed, H. A., Alhmoud, H., & Khan, R. A. (2025). Cyclosporine: Immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug. Transplant Immunology. https://doi.org/10.1016/j.trim.2024.102147
Vancouver
Alqadi R, Alqumia A, Alhomoud IS, Alhowail A, Aldubayan M, Mohammed HA, et al. Cyclosporine: Immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug. Transplant Immunology. 2025. doi:10.1016/j.trim.2024.102147
BibTeX
@article{Alqadi2025,
author = {Alqadi, Razan and Alqumia, Amal and Alhomoud, Ibrahim S and Alhowail, Ahmad and Aldubayan, Maha and Mohammed, Hamdoon A and Alhmoud, Hussam and Khan, Riaz A},
title = {Cyclosporine: Immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug},
journal = {Transplant Immunology},
year = {2025},
doi = {10.1016/j.trim.2024.102147}
}
EUVIMED